Renuka Ekka

Ms. Renuka Ekka


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 January 2026 in Pharmacological Research - Natural Products
Verified
Journal Article
Closed access
RERenuka Ekka
Renuka Ekka
BABharti Ahirwar
Bharti Ahirwar
SPSumathi Poleboina
Sumathi Poleboina

31 January 2026 in Research Journal of Pharmacognosy and Phytochemistry
Verified
Journal Article
Closed access
RERenuka Ekka
Renuka Ekka
SBShashikala Bhagat
Shashikala Bhagat
SSShubham Kumar Sahu
Shubham Kumar Sahu
BABharti Ahirwar
Bharti Ahirwar
Alzheimer’s disease is a progressive neurodegenerative disorder marked by cognitive decline, amyloid-beta accumulation, tau hyperphosphorylation, and chronic oxidative stress. Emerging evidence highlights mitochondrial dysfunction and impaired bioenergetics as central contributors to Alzheimer's disease pathogenesis. Centella asiatica a medicinal herb widely used in traditional systems of medicine, has demonstrated promising neuroprotective properties through its rich phytochemical profile, particularly triterpenoids such as asiaticoside and madecassoside. This review systematically explores the role of Centella asiatica in modulating mitochondrial bioenergetics and antioxidant pathways in the context of Alzheimer’s disease. Centella asiatica enhances mitochondrial function by upregulating ATP synthesis, preserving mitochondrial membrane potential, and promoting biogenesis via PGC-1α activation. Concurrently, it activates the Nrf2 signalling pathway, leading to increased expression of endogenous antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase. These mechanisms collectively reduce reactive oxygen species (ROS), mitigate lipid peroxidation, and prevent neuronal apoptosis. Preclinical studies support Centella asiatica's efficacy in improving cognitive performance, reducing neuroinflammation, and protecting against neurotoxicity. Although clinical data remain limited, the safety profile and multi-targeted action of Centella asiatica position it as a promising candidate for adjunctive therapy in Alzheimer’s disease. Further translational research and clinical trials are warranted to validate its therapeutic potential and optimise its pharmacological application.

12 August 2026 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
RERenuka Ekka
Renuka Ekka
BABharti Ahirwar
Bharti Ahirwar
Background Bauhinia variegata (L.), has been traditionally utilized by tribal communities for the treatment of inflammatory and infectious disorders. However, systematic scientific validation integrating pharmacognostic, phytochemical, experimental and computational strategies remain limited. Objective To scientifically validate the traditional medicinal claims of Bauhinia variegata by pharmacognostic evaluation, phytochemical quantification, antioxidant, antimicrobial, anti-inflammatory and in-silico studies. Materials and methods Ethanolic leaf extracts were prepared using the Soxhlet extraction method. Pharmacognostic evaluation included microscopic, physicochemical and phytochemical analyses. Flavonoid and phenolic contents were qualified and antioxidant, anti-inflammatory and antimicrobial activities were evaluated using established in vitro methods. Molecular docking studies of major flavonoids were performed against Cyclooxygenase-2 (COX-2) with diclofenac used as the reference standard. ADMET and drug-likeness properties were predicted using computational tools. Results The extract indicated high flavonoid content (TFC 446.85 ± 0.69) and considerable phenolic content (TPC 137.04 ± 1.14). Significant antioxidant activity was observed with IC50 values of 218.76 µg/ml (ABTS) and 217.59 µg/ml (FRAP). The extract demonstrated concentration-dependent anti-inflammatory activity and notable antimicrobial activity. Molecular docking revealed potentially binding affinities: rutin (-9.6), Quercetin (-9.2), Apigenin (-9.1), Kaempferol (-9.0), Catechin (-7.1), with docking scores lower than that of diclofenac (-6.7), suggesting stronger predicted interaction with the target protein. ADMET and drug-likeness analysis indicated favourable pharmacokinetic and safety profiles for the selected flavonoids. Conclusion the integrated experimental and in-silico findings scientifically validate the traditional use of Bauhinia variegata as a potent source of antimicrobial, antioxidant and anti-inflammatory activities. The strong docking scores and favourable ADME profiles of major flavonoids highlight their potential as promising therapeutic lead compounds for further drug development.